Clinical trials: Lymphatic System Neoplasm
Multiple Myeloma
SIL as Maintenance Therapy in Multiple Myeloma
The goal of this phase 2 trial is to test the safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma.
- Trial name
- NCT06744894
- Testing
- Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy
- Volunteers
- 50 people
- Sponsor
- Navy General Hospital, Beijing
Acute Lymphoblastic Leukemia, Pediatric
Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3
The current study will assess the acceptability and feasibility of the CareMeds intervention with a larger sample (N = 100) across multiple sites in Buffalo, NY, and Atlanta, GA.
- Trial name
- NCT06074666
- Testing
- CareMeds Intervention, Usual Care Group
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, B-Cell
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
This is a gene transfer study for patients with a type of blood cancer called Acute Lymphoblastic Leukemia (ALL) that has come back or has not gone away after treatment.
- Trial name
- TRICAR-ALL (NCT05010564)
- Testing
- Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00363272
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Myasthenia Gravis, Autoimmune Diseases of the Nervous System
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG.
- Conditions
- Myasthenia Gravis, Autoimmune Diseases of the Nervous System, Neuromuscular Junction Diseases, Thymoma
- Trial name
- NCT05214612
- Testing
- Drug treatment of myasthenia gravis and treatment of crisis
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL)
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
The purpose of this study is to see if conditioning regimens that include personalized rabbit ATG (P-rATG) help the immune system recover sooner and decrease the chances of transplant-related side effects.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT04872595
- Testing
- Personalized rATG (P-rATG), Hyper fractionated total body irradiation, Thiotepa
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
Laboratory and other studies suggest that, the study drug, Everolimus (RAD001), may prevent tumor cell growth and also may increase the efficacy of other chemotherapy drugs.
- Trial name
- CRAD001NUS175T (NCT01523977)
- Testing
- Everolimus, Prednisone, Vincristine
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Lymphoma
Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide in treating…
- Trial name
- NCT00020111
- Testing
- arsenic trioxide
- Where
- 52 sites in United States, Australia and 1 more
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
This is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT03674411
- Testing
- Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)
- Trial name
- NCT06115135
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Oncotherapeutics
Colorectal Cancer, Diarrhea
Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Colorectal Cancer, Diarrhea, Neutropenia
- Trial name
- NCT01164215
- Testing
- fluorouracil, leucovorin, oxaliplatin
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
This study was designed as a prospective, multicenter, open-label, randomized controlled trial. Eligible participants were patients aged 15-60 years with high-risk or relapsed/refractory acute myeloid leukemia (AML), acute…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell
- Trial name
- NCT07562568
- Testing
- SHR2554/AZA + Overlapped TBF, mBUCY conditioning regimen
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Lymphoblastic Leukemia
CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia
This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous chimeric antigen receptor (CAR) T cells targeting both CD19 and CD22, manufactured with T-Charge(TM) process.
- Trial name
- NCT05168748
- Testing
- IMJ995 single agent
- Sponsor
- Novartis Pharmaceuticals
Adult B Acute Lymphoblastic Leukemia
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Relapsed Refractory (R/R) adult acute lymphoblastic…
- Trial name
- NCT04626726
- Testing
- CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Aggressive B-Cell Non-Hodgkin Lymphoma
A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma
Tumour lysis syndrome (TLS) occurs as a consequence of the rapid destruction of malignant cells, spontaneously and/or in response to cytotoxic agents and immunotherapies.
- Trial name
- FRILLY (NCT05840289)
- Testing
- fractionated first dose rituximab
- Where
- Switzerland
- Volunteers
- 94 people
- Sponsor
- University Hospital, Geneva
Anemia, Multiple Myeloma
Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.
This is a multi-center open label, randomized phase-3 study with stratification according to diagnosis and baseline serum-EPO level.
- Conditions
- Anemia, Multiple Myeloma, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT00145652
- Testing
- Neo-Recormon and Venofer
- Where
- Sweden
- Volunteers
- 66 people
- Sponsor
- Sundsvall Hospital
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma
This randomized clinical trial studies how well a high-intensity intervention parenting program works in improving learning and school functioning in Latino children with acute leukemia or lymphoblastic lymphoma.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoblastic Lymphoma, Acute Leukemia
- Trial name
- NCT03178617
- Testing
- Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Myeloma, Plasma-Cell, Lymphoma, Malignant
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood
The purpose of this study is to determine whether a less-intensive preparative therapy followed by an allogeneic peripheral stem cell transplantation will provide an effective treatment for your disease and whether it will be…
- Conditions
- Myeloma, Plasma-Cell, Lymphoma, Malignant, Myeloproliferative Disorders, Myelodysplastic Syndromes
- Trial name
- NCT00146055
- Testing
- Reduced intensity conditioning with allogeneic transplant
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Michigan Rogel Cancer Center
Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia
Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT
This is a Phase 2 study designed for the purpose of estimating various parameters surrounding the efficacy of Clofarabine, Cyclophosphamide and Etoposide in eliminating minimal residual disease (MRD) in acute leukemia patients…
- Trial name
- NCT02349178
- Testing
- Clofarabine, Cyclophosphamide, Etoposide
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Medical College of Wisconsin
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down…
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
- Trial name
- NCT03914625
- Testing
- Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide
- Where
- 228 sites in United States, Australia and 3 more
- Volunteers
- 6,720 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.